FDA Accelerated Approval Pathway Under Scrutiny as Sarepta Seeks Traditional Approval Despite Failed DMD Trial
核心洞察
Sarepta Therapeutics plans to seek traditional FDA approval for two Duchenne muscular dystrophy (搜索) drugs despite their confirmatory trial failing to meet the primary endpoint.
Approximately 10% of all FDA drug approvals between 2018 and 2021 involved drugs that missed at least one primary endpoint in pivotal trials.
Critics argue the FDA has gone too far in allowing drugs with uncertain evidence to reach market, citing safety concerns and financial burdens on patients.
Sarepta Therapeutics announced this month that a confirmatory trial for two of its marketed Duchenne muscular dystrophy (搜索) (DMD) drugs failed to reach its primary endpoint, but the company is not abandoning the treatments. Instead, Sarepta plans to meet with the FDA to discuss "converting from an accelerated to traditional approval," based on other clinically meaningful changes observed in the 6- to 13-year-old study subjects.
This approach reflects a broader trend in pharmaceutical regulation where failed trials don't necessarily spell the end for drug candidates. Sarepta has successfully employed this strategy before—its DMD gene therapy Elevidys received full approval and a label expansion despite a late-stage trial failing to meet the primary endpoint.
Growing Concerns Over Regulatory Flexibility
The practice has drawn sharp criticism from medical experts who argue that failed trials should represent definitive endpoints. "There's no wiggle room in my mind," said Dr. Joseph Ross, professor of medicine and public health at the Yale School of Medicine. "I cannot understand how a trial that's designed to demonstrate whether a drug works or not, if it fails, how a drug could then get approved for use. Because what was the point of the trial?"
Ross emphasizes that trials are already designed to give products the best possible chance of demonstrating benefit. "And so if it's null, it's null," he said.
The scope of this issue extends beyond individual cases. According to a study co-authored by Ross, approximately 10% of all FDA approvals between 2018 and 2021 involved a drug that missed at least one primary endpoint in a pivotal trial.
The Accelerated Approval Pathway
The FDA's accelerated approval pathway provides more latitude for drugs treating serious diseases like DMD that have limited treatment options. Companies can gain rapid approval based on surrogate endpoints—laboratory results or other measures suggesting potential efficacy—without demonstrating clear clinical benefit. However, they must confirm results through follow-up trials to maintain full approval, with the risk of market withdrawal if unsuccessful.
"I have been among the chorus of people thinking that the FDA has gone too far towards allowing drugs to reach the market with too much uncertainty in terms of the evidence," Ross said. "But it's not just the FDA. They're constantly pushed in that direction by Congress, industry and patient advocacy organizations."
Mixed Track Record
The accelerated approval pathway has produced notable successes, including expedited access to life-saving HIV (搜索) antiretroviral drugs. However, it has also led to significant failures and patient harm.
Pfizer's Oxbryta received accelerated FDA approval in 2019 but was later withdrawn over safety concerns, including reports of several patient deaths. Similarly, Biogen and Eisai's Alzheimer's drug Aduhelm gained approval despite one of its two phase 3 trials failing. While the drug demonstrated reduction in amyloid plaque (搜索) in the brain, it showed only modest improvement in clinical symptoms and was eventually pulled from the market after insurers and CMS pushed back on coverage.
A 2022 Office of Inspector General report found additional problems with the system, noting that companies often moved too slowly with required follow-up trials, with many remaining incomplete or late.
Financial and Safety Implications
The approval of drugs without clear evidence of benefit raises significant concerns about both safety and costs. "Some of these very expensive gene therapies, biologics and other specialty drugs can bankrupt families," Ross noted. The broader public also bears financial burden through higher insurance premiums and other costs.
Ross advocates for more stringent FDA standards to protect patients. "My general feeling has been, if we as a society are going to allow products to get approved with less certain evidence so they can to reach patients sooner, we need to do a better job of ensuring that companies are completing the confirmatory trials in the post-market period within a reasonable period of time, so we know they work and that patients aren't wasting their money."
Proposed Solutions
To address these concerns, Ross suggests creating an evidence-generation system using existing data sources to monitor product safety and efficacy beyond clinical trials. Such increased oversight could help restore balance between providing faster access to promising treatments while maintaining scientific rigor.
The stakes extend beyond individual drugs to broader public health implications. "It diminishes the confidence the public has in the FDA," Ross warned, highlighting the need for regulatory reforms to maintain both patient access and scientific integrity.